Amgen sells 360-worker facility to Boehringer; U.K.'s watchdog broadens use of Alzheimer's meds;

 @FiercePharma: Another J&J recall, another hit to J&J's image. Article | Follow @FiercePharma

> Amgen will sell its Fremont, California, research and manufacturing operations to Boehringer Ingelheim for an undisclosed price; 360 employees currently work there. Report

> Biomarkers finally get respect, but challenges remain. Article 

> Israeli researcher finds blood cancer biomarkers. Item 

> Pfizer and Eisai's Aricept, Shire's Reminyl and Novartis' Exelon won backing from the U.K. cost-effectiveness watchdog for expanded use in patients with mild or moderate Alzheimer's disease, in addition to more severe illness. News

> There is not enough evidence to recommend widespread use of statins like Pfizer's Lipitor or AstraZeneca's Crestor in people with no previous history of heart disease, scientists said in a new review. Story

> Mylan shares jumped in trading after the generic drugmaker said it received approval to make three doses of a generic version of Bayer's Precose tablets, which are used to treat diabetes. Mylan release | Item

> GlaxoSmithKline has started a pivotal study testing intravenous zanamivir, approved in inhaled form as Relenza, against Roche's best-selling pill Tamiflu as a treatment for patients hospitalised with influenza. Article

> J&J job ads emphasize change in focus. News 

> San Diego's Cadence Pharmaceuticals said that it has launched Ofirmev, the first intravenous formulation of acetaminophen, in the U.S.; it won FDA approval in November. Report

> Colin Mackenzie has been appointed the new president of GlaxoSmithKline Consumer Healthcare North America, succeeding Roger Scarlett-Smith, who will become president of GSK Consumer Healthcare Europe. News

> DNA overexpression might be cancer biomarker. Report 

> Canada risks losing out on the next wave of lucrative pharmaceutical investment and jobs unless it matches tougher patent protection for drugmakers in the U.S. and Europe, says a new report for the Canadian Chamber of Commerce. Story

> Biomarkers are biting on scientific fishing expedition. Article

> Takeda, Zinfandel double-team Alzheimer's biomarker. Item  

Biotech News

 @FierceBiotech: Feds' $1B antiterror drug development program yields little. News | Follow @FierceBiotech

 @JohnCFierce: Ariad shares shot up 36% on this morning's sarcoma data. Three weeks isn't much time, but deadly cancers have their own metric for success. | Follow @JohnCFierce 

> Pfizer, Theraclone ink $632 R&D deal for cancer, infectious disease. News 

> Roche, Plexxikon melanoma drug extends patients' lives. Article 

> pSivida raises $11M in RDO. Story 

> Ironwood, Protagonist ink peptide discovery deal. Report 

Drug Delivery News

> Lincoln Pharma gets patent for nasal delivery of anti-vomiting drug. Story 

> Hot gold nanoparticles can cook cancer cells. Report 

> Spider silk protein could make terrific delivery device. Item 

> Cancer cells hit with a 'Big Mac' attack. Article 

> A magnet car for your GI tract could deliver meds. Story

Medical Device News

> PwC: Emerging med tech markets catching up to U.S. Item

> Smiths Group rejects $3.9B offer for medical unit. Story 

> S&N: We're not in merger talks. Report 

> Report: iWalk raises $15M. News 

> Obama: FDA med device changes coming today. Article 

> Tornier releases IPO terms. Report

> Oval Medical raises cash, reports positive study results. News 

And Finally... Two online communities for doctors have launched a strategic alliance to help them expand their reach internationally, aiming for business from the pharma industry. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.